Skip to content
value.today

Kinex Pharmaceuticals LLC

Total raised
$347 M
8 rounds on record
Latest round
$60 M
Dec 2019
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Kinex Pharmaceuticals LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$60 MNo. 8$50 to $250 million

Kinex Pharmaceuticals LLC: Raise no. 8, Dec 2019

Investors in this round

5 investors had bought by the notice of Dec 11, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Yordon · Executive Officer
  • Johnson Lau · Executive Officer, Director
  • Randoll Sze · Executive Officer
  • Rudolf Kwan · Executive Officer
  • Simon Pedder · Executive Officer
  • William Zuo · Executive Officer
  • Benson Tsang · Director
  • Jinn Wu · Director
  • John Koh · Director
  • John Vierling · Director
  • Jordan Kanfer · Director
  • Kim Campbell · Director
  • Manson Fok · Director
  • Stephanie Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SunTrust Robinson Humphrey, Inc. (CRD 6271) · Atlanta, GeorgiaSold in CT, NY

Signed by Teresa Bair, Corporate Secretary. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC.

equitySEC
May 2019$100 MNo. 7$50 to $250 million

Kinex Pharmaceuticals LLC: Raise no. 7, May 2019

Investors in this round

4 investors had bought by the notice of May 15, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Yordon · Executive Officer
  • Johnson Lau · Executive Officer, Director
  • Randoll Sze · Executive Officer
  • Rudolf Kwan · Executive Officer
  • Simon Pedder · Executive Officer
  • William Zuo · Executive Officer
  • Benson Tsang · Director
  • Jinn Wu · Director
  • John Koh · Director
  • John Vierling · Director
  • Jordan Kanfer · Director
  • Kim Campbell · Director
  • Manson Fok · Director
  • Stephanie Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Teresa Bair, Corporate Secretary. Source: SEC Form D, newest notice filed May 15, 2019. Read the notice at the SEC.

equitySEC
Jun 2018$50 MNo. 6$50 to $250 million

Kinex Pharmaceuticals LLC: Raise no. 6, Jun 2018

Investors in this round

1 investor had bought by the notice of Jul 17, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Kwan Hung Yordon · Executive Officer
  • Johnson Lau · Executive Officer
  • Li Kwan Hung Shen · Executive Officer
  • Rudolf Kwan Hung Kwan · Executive Officer
  • Simon Kwan Hung Pedder · Executive Officer
  • William Kwan Hung Zuo · Executive Officer
  • Benson Kwan Hung Tsang · Director
  • Jinn Wu · Director
  • Kim Campbell · Director
  • Manson Fok · Director
  • Sheldon Trainor-Degirolamo · Director
  • SongYi Zhang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in item 3.”

Signed by Johnson Lau, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2018. Read the notice at the SEC.

equity, optionsSEC
Apr 2015$48 MNo. 5$10 to $50 million

Kinex Pharmaceuticals LLC: Raise no. 5, Apr 2015

Investors in this round

9 investors had bought by the notice of May 20, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $63 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Flint Besecker · Executive Officer, Director
  • Johnson Lau · Executive Officer, Director
  • Charles Lannon · Director
  • Jinn Wu · Director
  • Michael Murphy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Flint Besecker, Chief Operating Officer and Executive Vice President. Source: SEC Form D, newest notice filed May 20, 2015. Read the notice at the SEC.

equitySEC
Apr 2015$10 MIssued in a merger or acquisition$10 to $50 million

Kinex Pharmaceuticals LLC: Private sale, Apr 2015

Investors in this round

2 investors had bought by the notice of Jun 16, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Flint Besecker · Executive Officer, Director
  • Johnson Lau · Executive Officer, Director
  • Jinn Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Stock was issued in connection with an acquisition by the Company.”

Signed by Flint Besecker, Board Director and Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC.

equitySEC
Mar 2015$74 MNo. 4$50 to $250 million

Kinex Pharmaceuticals LLC: Raise no. 4, Mar 2015

Investors in this round

9 investors had bought by the notice of Jun 16, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$74 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Flint Besecker · Executive Officer, Director
  • Johnson Lau · Executive Officer, Director
  • Jinn Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Flint Besecker, Board Director and Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC.

equitySEC
Jul 2012$5 MNo. 3$2 to $10 million

Kinex Pharmaceuticals LLC: Raise no. 3, Jul 2012

Investors in this round

1 investor had bought by the notice of Aug 6, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $40 M offered; $35 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David Hangauer · Executive Officer
  • Johnson Lau · Executive Officer, Director
  • Lyn Dyster · Executive Officer
  • Charles Lannon · Director
  • Flint Besecker · Director
  • Jean-Pierre Sommadossi · Director
  • Jinn Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Officer salaries”

Signed by Lyn Dyster, Vice President. Source: SEC Form D, newest notice filed Aug 6, 2012. Read the notice at the SEC.

equitySEC
Apr 2011$5 MNo. 2$2 to $10 million

Kinex Pharmaceuticals LLC: Raise no. 2, Apr 2011

Investors in this round

2 investors had bought by the notice of Apr 25, 2011: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $0 M still to sell
Smallest investment taken
$250,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Allen Barnett · Executive Officer, Director
  • David Hangauer · Executive Officer
  • Johnson Lau · Executive Officer, Director
  • Lyn Dyster · Executive Officer
  • Charles Lannon · Director
  • David Hsia · Director
  • Jinn Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Officer salaries”

Signed by Allen Barnett, Ceo. Source: SEC Form D, newest notice filed Apr 25, 2011. Read the notice at the SEC.

equitySEC
Dec 2009$4 MNo. 1$2 to $10 million

Kinex Pharmaceuticals LLC: Raise no. 1, Dec 2009

Investors in this round

24 investors had bought by the notice of Feb 3, 2010: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Allen Barnett · Executive Officer, Director
  • David Hangauer · Executive Officer
  • Johnson Lau · Executive Officer, Director
  • Lyn Dyster · Executive Officer
  • Charles Lannon · Director
  • David Hsia · Director
  • Jinn Wu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Officer salaries”

Signed by Allen Barnett, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Feb 3, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kinex Pharmaceuticals LLC chose not to state its revenue in its newest notice of a funding round (Dec 2019).

    SEC Form D · Dec 2019

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2011; revenue between $1 million and $5 million in 2012; revenue between $25 million and $100 million in 2019.

    SEC Form D (revenue range) · May 2019

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Dec 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kinex Pharmaceuticals LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kinex Pharmaceuticals LLC
NameRoleNamed in
Jeffrey YordonExecutive officerDec 2019
Johnson LauExecutive officerDec 2019
Randoll SzeExecutive officerDec 2019
Rudolf KwanExecutive officerDec 2019
Simon PedderExecutive officerDec 2019
William ZuoExecutive officerDec 2019
Jeffrey Kwan Hung YordonExecutive officerJul 2018
Li Kwan Hung ShenExecutive officerJul 2018
Rudolf Kwan Hung KwanExecutive officerJul 2018
Simon Kwan Hung PedderExecutive officerJul 2018
William Kwan Hung ZuoExecutive officerJul 2018
Flint BeseckerExecutive officerJun 2015
David HangauerExecutive officerAug 2012
Lyn DysterExecutive officerAug 2012
Allen BarnettExecutive officerApr 2011
Benson TsangDirectorDec 2019
Jinn WuDirectorDec 2019
John KohDirectorDec 2019
John VierlingDirectorDec 2019
Johnson LauDirectorDec 2019
Jordan KanferDirectorDec 2019
Kim CampbellDirectorDec 2019
Manson FokDirectorDec 2019
Stephanie DavisDirectorDec 2019
Benson Kwan Hung TsangDirectorJul 2018
Sheldon Trainor-DegirolamoDirectorJul 2018
SongYi ZhangDirectorJul 2018
Flint BeseckerDirectorJun 2015
Charles LannonDirectorMay 2015
Michael MurphyDirectorMay 2015
Jean-Pierre SommadossiDirectorAug 2012
Allen BarnettDirectorApr 2011
David HsiaDirectorApr 2011